PT  - JOURNAL ARTICLE
AU  - Ader, Florence
AU  - Bouscambert-Duchamp, Maude
AU  - Hites, Maya
AU  - Peiffer-Smadja, Nathan
AU  - Poissy, Julien
AU  - Belhadi, Drifa
AU  - Diallo, Alpha
AU  - Delmas, Christelle
AU  - Saillard, Juliette
AU  - Dechanet, Aline
AU  - Fougerou, Claire
AU  - Lê, Minh-Patrick
AU  - Peytavin, Gilles
AU  - Mercier, Noémie
AU  - Velou, Priyanka
AU  - Tubiana, Sarah
AU  - Lescure, Xavier
AU  - Faure, Emmanuel
AU  - Nseir, Saad
AU  - Richard, Jean-Christophe
AU  - Wallet, Florent
AU  - Goehringer, François
AU  - Lefèvre, Benjamin
AU  - Kimmoun, Antoine
AU  - Raffi, François
AU  - Gaborit, Benjamin
AU  - Reignier, Jean
AU  - Lanoix, Jean-Philippe
AU  - Andrejak, Claire
AU  - Zerbib, Yoann
AU  - Bani-Sadr, Firouzé
AU  - Mourvilliers, Bruno
AU  - Danion, François
AU  - Ruch, Yvon
AU  - Clere-Jehl, Raphaël
AU  - Le Moing, Vincent
AU  - Klouche, Kada
AU  - Lacombe, Karine
AU  - Martin-Blondel, Guillaume
AU  - Vardon-Bounes, Fanny
AU  - Cabié, André
AU  - Turmel, Jean-Marie
AU  - Piroth, Lionel
AU  - Blot, Mathieu
AU  - Botelho-Nevers, Élisabeth
AU  - Gagneux-Brunon, Amandine
AU  - Thiery, Guillaume
AU  - Bénézit, François
AU  - Gaci, Rostane
AU  - Mootien, Joy
AU  - Gallien, Sébastien
AU  - Garot, Denis
AU  - Bouiller, Kevin
AU  - Epelboin, Loïc
AU  - Jauréguiberry, Stéphane
AU  - Gaymard, Alexandre
AU  - Verschelden, Gil
AU  - Braz, Sandra
AU  - Ferreira Ribeiro, Joao Miguel
AU  - Joannidis, Michael
AU  - Staub, Thérèse
AU  - Altdorfer, Antoine
AU  - Greil, Richard
AU  - Egle, Alexander
AU  - Guedj, Jérémie
AU  - Noret, Marion
AU  - Roncon-Albuquerque, Roberto
AU  - Paiva, Jose-Artur
AU  - Lina, Bruno
AU  - Costagliola, Dominique
AU  - Yazdanpanah, Yazdan
AU  - Burdet, Charles
AU  - Mentré, France
TI  - Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
AID  - 10.1101/2022.03.30.22273206
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.30.22273206
4099  - http://medrxiv.org/content/early/2022/03/31/2022.03.30.22273206.short
4100  - http://medrxiv.org/content/early/2022/03/31/2022.03.30.22273206.full
AB  - Background The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in hospitalised patients with COVID-19, with indication of oxygen and/or ventilator support. Following prior publication of preliminary results, here we present the final results after completion of data monitoring.Methods In this European multicentre, open-label, parallel-group, randomised, controlled trial (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard of care (SoC) alone or in combination with remdesivir, lopinavir/ritonavir, lopinavir/ritonavir and IFN-β-1a, or hydroxychloroquine. Adult patients hospitalised with COVID-19 were eligible if they had clinical evidence of hypoxemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzyme, severe chronic kidney disease, any contra-indication to one of the studied treatments or their use in the 29 days before randomization, or use of ribavirin, as well as pregnancy or breast-feeding. Here, we report results for remdesivir + SoC versus SoC alone. Remdesivir was administered as 200 mg infusion on day 1, followed by once daily infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. Treatment assignation was performed via web-based block randomisation stratified on illness severity and administrative European region. The primary outcome was the clinical status at day 15 measured by the WHO 7-point ordinal scale, assessed in the intention-to-treat population.Findings Between March 22nd, 2020 and January 21st, 2021, 857 participants were randomised to one of the two arms in 5 European countries and 843 participants were included for the evaluation of remdesivir (control, n=423; remdesivir, n=420).At day 15, the distribution of the WHO ordinal scale was as follow in the remdesivir and control groups, respectively: Not hospitalized, no limitations on activities: 62/420 (14.8%) and 72/423 (17.0%); Not hospitalized, limitation on activities: 126/420 (30%) and 135/423 (31.9%); Hospitalized, not requiring supplemental oxygen: 56/420 (13.3%) and 31/423 (7.3%); Hospitalized, requiring supplemental oxygen: 75/420 (17.9%) and 65/423 (15.4%); Hospitalized, on non-invasive ventilation or high flow oxygen devices: 16/420 (3.8%) and 16/423 (3.8%); Hospitalized, on invasive mechanical ventilation or ECMO: 64/420 (15.2%) and 80/423 (18.9%); Death: 21/420 (5%) and 24/423 (5.7%). The difference between treatment groups was not statistically significant (OR for remdesivir, 1.02, 95% CI, 0.62 to 1.70, P=0.93). There was no significant difference in the occurrence of Serious Adverse Events between treatment groups (remdesivir, n=147/410, 35.9%, versus control, n=138/423, 32.6%, p=0.29).Interpretation Remdesivir use for the treatment of hospitalised patients with COVID-19 was not associated with clinical improvement at day 15.Funding European Union Commission, French Ministry of Health, DIM One Health Île-de-France, REACTing, Fonds Erasme-COVID-ULB; Belgian Health Care Knowledge Centre (KCE), AGMT gGmbH, FEDER “European Regional Development Fund”, Portugal Ministry of Health, Portugal Agency for Clinical Research and Biomedical Innovation. Remdesivir was provided free of charge by Gilead.Competing Interest StatementDr. Costagliola reports grants and personal fees from Janssen, personal fees from Gilead, outside the submitted work. Dr. Mentre reports grants from INSERM Reacting (French Government), grants from Ministry of Health (French Government), grants from European Commission, during the conduct of the study; grants from Sanofi, grants from Roche, outside the submitted work. Dr. Hites reports grants from The Belgian Center for Knowledge (KCE), grants from Fonds Erasme-COVID-ULB, during the conduct of the study; personal fees from Gilead, outside the submitted work. Dr. Mootien reports non-financial support from GILEAD, outside the submitted work. Dr. Gaborit reports non-financial support from Gilead, non-financial support from MSD, outside the submitted work. Dr. Botelho-Nevers reports other from Pfizer, other from Janssen, outside the submitted work. Dr. Lacombe reports personal fees and non-financial support from Gilead, personal fees and non-financial support from Janssen, personal fees and non-financial support from MSD, personal fees and non-financial support from ViiV Healthcare, personal fees and non-financial support from Abbvie, during the conduct of the study. Dr. Wallet reports personal fees and non-financial support from Jazz pharmaceuticals, personal fees and non-financial support from Novartis, personal fees and non-financial support from Kite-Gilead, outside the submitted work. Dr. Kimmoun reports personal fees from Aguettan, personal fees from Aspen, outside the submitted work. Dr. Thiery reports personal fees from AMGEN, outside the submitted work. Dr. Burdet reports personal fees from Da Volterra, personal fees from Mylan Pharmaceuticals, outside the submitted work. Dr. Poissy reports personal fees from Gilead for lectures, outside the submitted work. Dr. Goehringer reports personal fees from Gilead Sciences, non-financial support from Gilead Sciences, grants from Biomerieux, non-financial support from Pfizer, outside the submitted work. Dr. Peytavin reports personal fees from Gilead Sciences, personal fees from Merck France, personal fees from ViiV Healthcare, personal fees from TheraTechnologies, outside the submitted work. Dr. Danion reports personal fees from Gilead, outside the submitted work. Dr. Raffi reports personal fees from Gilead, personal fees from Janssen, personal fees from MSD, personal fees from Abbvie, personal fees from ViiV Healthcare, personal fees from Theratechnologies, personal fees from Pfizer, outside the submitted work. Dr. Gallien reports personal fees from Gilead, personal fees from Pfizer, personal fees from ViiV, personal fees from MSD, outside the submitted work; and has received consulting fee from Gilead in August 2020 to check the registration file of remdesivir for the French administration. Dr. Nseir reports personal fees from MSD, personal fees from Pfizer, personal fees from Gilead, personal fees from Biomerieux, personal fees from BioRad, outside the submitted work. Dr. Lefevre reports personal fees from Mylan, personal fees from Gilead, outside the submitted work. Dr. Guedj reports personal fees from Roche, outside the submitted work. Other authors have nothing to disclose.Clinical TrialNCT04315948Funding StatementThis work received funding from several sources: Europe: European Union Horizon 2020 research and innovation programme Austria: AGMT gGmbH Belgium: Belgian Health Care Knowledge Centre; Fonds Erasme-COVID-ULB France: REACTing, a French multi-disciplinary collaborative network working on emerging infectious diseases; Ministry of Health; Paris Ile-de-France Region Luxemburg: European Regional Development Fund Portugal: Ministry of Health; Agency for Clinical Research and Biomedical Innovation Remdesivir was provided by Gilead free of charge. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Centre de Protection des Personnes Ile-de-France-III, approval #20.03.06.51744I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors